Diligence memo · auto-generated · as of July 2, 2026

3F Bio Ltd

3F Bio Ltd looks fair against its niche peers and is quiet on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

3F Bio Ltd operates in Biotech / Pharma, based in GLASGOW, SCOTLAND.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

3F Bio Ltd has raised $7.2M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $7.2M on 2024-02-08.

Most recent recorded round closed around 2024-02-08.

Valuation (modeled)modeled

Provath models 3F Bio Ltd at approximately $45M (range $8.1M–$107M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.17× the median modeled value of Series A Biotech / Pharma companies in 2022–2024 (21 peers) — value vs value, same stage and era. Within the normal band (117% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 2.4 yr ago; this sector typically re-raises about every 15 months.

Slightly overdue versus sector cadence.

Comparablesmixed

Capital scale ranks ahead of 57% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 59% of those peers.

Closest niche peers: Laxmi Therapeutic Devices, Inc., Accipiter Biosciences Inc., Nanospectra Biosciences Inc, Ten Bay Bio, Inc., Genomic Life, Inc..

Peoplefiled

7 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.